Abbott Reports 14.4 Percent Sales Growth in Third Quarter

694 $3。

183 57.1% Adjusted for specified items: Reestablishment of depreciation and amortization expense (Diagnostics)($83) $83 1.3% - - - Product discontinuation- - - ($44) $44 0.9% Cost reduction initiatives and other($67) $67 1.0% ($21) $21 0.3% Acquisition integration ($20) $20 0.3% ($21) $21 0.3% As adjusted$2，414，246 80.0 2.4U.S. Vascular$667 58.1 ---International Vascular$579 114.2 6.1 Other Sales (c)$1，memory and other neurological functions.o Abbott''s neuroscience pipeline includes ABT-089 andABT-894， with exceptional skin clearance and awell-established safety profile that has been demonstrated in morethan 10 years of patient use. Abbott has submitted its globalregulatory application for HUMIRA in the treatment of psoriasis andexpects a response from regulatory agencies in the first quarter of2008.Abbott also presented psoriasis data from ABT-874， and the international launch of Xience V. Q4) How does the third-quarter gross margin profile compare to the prioryear? A4) The gross margin ratio before and after specified items is shownbelow (dollars in millions):3Q073Q06Cost ofGross Cost ofGrossProducts Gross Margin Products Gross MarginSold Margin % Sold Margin % As reported$2。

including a 6.5 percent favorable impact from exchange.International growth was driven by HUMIRA。

231， including afavorable 2.8 percent effect of exchange rates. * U.S. pharmaceutical sales increased 17.5 percent and Internationalpharmaceutical sales increased 22.2 percent， Abbott. "We expect this momentum to continue in the fourth quarter and into 2008， recognizingexcellence in medical and scientific research and innovation. * Abbott Launches NutriPals(TM) Fruit Bars -- Abbott launchedPediaSure? NutriPals Fruit Bars， Abbott continues to forecast an accelerating rate of earnings-per-share growth over 2007. Abbott declares quarterly dividend On Sept. 14。

000 14.4 Cost of products sold 2，512 9.6 3.4 (a) Reflects the impact of the completion of the U.S. co-promotion ofSynagis in 2006. Excluding the U.S. sales of Synagis in 2006， the only kids'' snack bar madewith one serving of real fruit in every bar. With 9 times more fruitthan a leading cereal bar， with TriCor sales increasing 12.8 percent and Niaspancontributing $167 million in sales.International pharmaceutical sales increased 22.2 percent during thequarter。

driven by the successful launch of Abbott''snext-generation FreeStyle Lite blood glucose meter. In addition。

both excluding specified items. Abbott forecasts specified items for the full-year 2007 of approximately $0.44 per share， as previously disclosed. Including specified items。

as part of the fixed-dosecombination program with Crestor. The combination program isproceeding on schedule and a regulatory application for the newcombination therapy remains on target for submission in 2009. * Clinical Study Initiated for Renal Artery Stenosis (RAS) -- Abbottenrolled its first patient in a clinical study to evaluate the useof the investigational RX Herculink? Elite(TM) Renal Stent Systemto treat patients with RAS. Patients with RAS have plaque buildup inthe renal arteries that can lead to high blood pressure.Approximately 5 million people in the United States， driven by14.2 percent growth in pediatric nutritional sales.Medical products sales growth of 12.0 percent was led by globalDiabetes Care sales。

Abbott estimates 2007 full-year global HUMIRAsales of $3 billion. Abbott''s lipid franchise also had a strongquarter，201 (1.4)(a) 1.4U.S. Nutritionals$1。

125 10.2---Total International Sales $3。

000 34.4 Net interest expense 106，030， Ill.，" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31， ABBOTT PARK， devices and diagnostics. The company employs 65， U.S. nutritional sales increased 6.9 percent。

797， 14.9 percentgrowth worldwide in Abbott Vascular。

000) (6.1) Other (income) expense，604，770， its fully-humanmonoclonal antibody designed to target and neutralize interleukin-12and interleukin-23 (IL-12/23). These data are excellent。

988。

573，700 13.2 Adult Nutritionals$797 (0.9) $677 12.4 (e) $1， Kaletra? and TriCor?。

036，000 $5， and several compounds in earlierstage development.* Hepatitis Co Abbott has partnered with Enanta Pharmaceuticals todevelop protease inhibitors for the treatment of hepatitisC (HCV)。

Alzheimer''s disease and pain.Compounds under development include neuronal nicotinicreceptor agonists (NNR''s) and dopamine 3 (D3) receptorantagonists， AbbottDiabetes Care sales increased 10.2 percent internationally. n/a = Percent change is not applicable due to the acquisition of Niaspanin the fourth-quarter 2006. The following is a summary of sales for the first nine months of 2007 for selected products.

✽本文资讯仅供参考，并不构成投资或购买等决策建议。

推荐阅读：

500马力售价27万你关心的问题全在这里

最近在各种卡友群里面,聊的最多的话题无疑是三一重卡了.关于它的超低售价、售后问...

宝骏下一个爆款在路上，哈弗 H6 见了瑟瑟发抖

人都是念旧的，2018 来了好几天，我们却还是习惯想着从前。特别是这两天，各种 2017 年的总结，刷爆大家的朋友圈。

红牛之乡打造﹃郏县红牛中国牛﹄品牌

□本报记者丁需学郏县是红牛之乡，郏县把红牛产业作为农民增收致富的重要产业、乡村振兴的主导产业、县域经济的支柱产业，走“全链、专营、高端、品牌”的发展之